Eywa Pharma Inc secured FDA approval for its ANDA 210211 covering Hydrocodone Bitartrate and Acetaminophen oral tablets, thereby granting the company a license to manufacture a generic version of the opioid painkiller and positioning it to capture market share in the established generic healthcare space.